BiVictriX Therapeutics plc Employee Directory

Biotechnology ResearchEngland, United Kingdom11-50 Employees

BiVictriX is developing next-generation bispecific ADCs (bsADCs) designed to deliver superior tumour targeting, even in cancers with ultralow antigen expression. Our BI-CYGNI® platform unlocks new treatment possibilities across hard-to-treat cancers through rational, tumour-restricted antigen pairing.

Existing antibody-based approaches have shown considerable therapeutic benefit in a number of cancer indications, however the wider application of these drugs to more challenging settings is limited by the shared expression of the targeted antigens on healthy tissues. Thus leading to debilitating and sometimes fatal toxic side-effects associated with treatment. The lack of true cancer specificity seen with existing platforms has resulted in many antibody-based therapeutics being removed from the clinic and is one of the major factors limiting the development of this otherwise promising therapeutic class.

BiVictriX's Bi-Cygni therapeutics are engineered to selectively target unique cancer-specific twin antigen fingerprints, which are largely absent from healthy cells. The Bi-Cygni approach links the Company's in-house panel of cancer-restricted twin antigen fingerprints to generate the next generation of bispecific ADC therapeutics with enhanced therapeutic index, across a broad range of malignant indications.

Sign up for free to view info

Company overview Email format